Morphine, Buprenorphine, and Other Drugs Market Reaches USD 9.94 Billion in 2026, Driven by Rising Demand for Effective Pain Management and Opioid Dependence Treatment

Advancements in Drug Delivery Systems and Expanding Access to Opioid Use Disorder Therapies to Drive Morphine, Buprenorphine, and Other Drugs Market to USD 13.97 Billion by 2033 at 6.2% CAGR – Coherent Market Insights

Morphine, Buprenorphine, and Other Drugs Market, by Drug (Morphine, Buprenorphine, Noscapine, Thebaine, and Etrophine), by Application (Pain Management, Opioid Addiction Treatment, and Others), by Route Of Administration (Injectable, Oral, and Transdermal), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 9.94 Bn in 2026 and is expected to exhibit a CAGR of 6.2% during the forecast period (2026-2033), as highlighted in a new report published by Coherent Market Insights.

Rising authorization of drugs for opioid addiction treatment is expected to propel growth of the morphine, buprenorphine, and other drugs market over the forecast period. For instance, in February 2019, Sandoz (Novartis division) announced marketing authorization for the generic SUBOXONE 1 which is combination of naloxone and buprenorphine, to be available in different dosage strengths in the U.S. The drug is indicated for the treatment of opioid dependence. Hence, such complete treatment plans of buprenorphine and naloxone sublingual film are propelling the market growth.

Browse 30 Market Data Tables and 36 Figures spread through 358 Pages and in-depth TOC on “Global Morphine, Buprenorphine, and Other Drugs Market” Forecast 2033 - by Drug (Morphine, Buprenorphine, Noscapine, Thebaine, and Etrophine), by Application (Pain Management, Opioid Addiction Treatment, and Others), by Route Of Administration (Injectable, Oral, and Transdermal), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Morphine, Buprenorphine, and Other Drugs Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/morphine-buprenorphine-and-other-drugs-market-4637

Furthermore, the development and launch of opioid drugs is expected to aid in the growth of the global morphine, buprenorphine, and other drugs market. For instance, in March 2019, Piramal Critical Care launched the Morphine Sulfate injection in the U.S. with trademark of Mitigo used for intractable chronic pain treatment. Morphine Sulfate injection is used for treating moderate to severe pain. It is majorly used for pain associated with surgery, myocardial infraction, and cancer. Hence, such launch of new products is expected to boast the morphine, buprenorphine, and other drugs market.

Key Takeaways of the Morphine, Buprenorphine, and Other Drugs Market

• Morphine, buprenorphine, and other drugs market is expected to exhibit a CAGR of 6.2% during the forecast period owing to the rising research and development activities by academic institutes. For instance, in April 2018, Stanford University Bioengineers, developed a new anticancer medicine and cough suppressant medicine noscapine by a new method for production based on fermentation of enzymes obtained from mammals, medicinal plants and microorganisms to make the drug. These type of new natural techniques for the production of this medicine are necessary as recently opium poppy is the only feasible source but is limited due to expensive controls and regulations. Thus new types of techniques for opioid drug production are expected to propel the market growth.
• Among drug, buprenorphine segment is expected to have highest CAGR for the morphine, buprenorphine, and other drugs market during forecast period, owing to research and development and use of buprenorphine along with other drugs for opioid addiction treatment. For instance, WHO has recommend range of treatment options to the patients for opioid dependence. These include opioid (with medicines such as buprenorphine and methadone) for agonist maintenance treatment, pharmacological treatment with antagonist opioids (such as naltrexone). WHO supports countries in improving the quality and coverage of programmes for treatment for opioid dependence and introducing them where they do not already exist due to which morphine, buprenorphine and other drugs market is expected to grow rapidly.
• On the basis of application, pain management segment is expected to exhibit highest CAGR owing to use of opioids for cancer pain, myocardial infraction surgery, and other postsurgical pain and chronic pain management.
• On the basis of route of administration, oral segment accounted for highest market share owing to convenience of use of the patients. Oral opioids are commonly prescribed for cough and diarrhea. Further opioids are also used for pain management and cancer treatment and thus owing to highest market share in morphine, buprenorphine, and other drugs market.
• On the basis of distribution channel, retail pharmacies segment is estimated to hold a dominant position in the morphine, buprenorphine, and other drugs market over the forecast period.
• Among the regions, North America region accounted for the largest market share in morphine, buprenorphine, and other drugs market in 2026. Recently opioids such as buprenorphine are largely used in the U.S. for opioid use disorder treatment, thus morphine, buprenorphine, and other drugs market has accounted for largest market share.
• Major players operating in the morphine, buprenorphine, and other drugs market include Purdue Pharma, Sun Pharmaceuticals, Pfizer Inc, West Ward Pharmaceuticals, Teva Pharmaceuticals, Piramal Pharmaceuticals, Hikama Pharmaceuticals, Indivior PLC, Oreoxo AB, Camurus AB, and Novartis.

Key Development

• In May 2026, Indivior Pharmaceuticals Inc, pharmaceuticals company announced positive findings from two real-world studies evaluating extended-release buprenorphine, commercially available as SUBLOCADE. Patients who adhered to monthly injectable buprenorphine were significantly less likely to return to opioid use than patients receiving other medication-based treatments. A separate study found that these patients experienced a 62% lower incidence of bloodstream infections, along with fewer inpatient, emergency-department, and outpatient visits. The findings strengthen the clinical and economic case for long-acting buprenorphine formulations in opioid use disorder treatment.
• In May 2026, Braeburn presented positive data concerning its weekly and monthly injectable buprenorphine treatment, BRIXADI, at the American Society of Clinical Psychopharmacology Annual Meeting. An exploratory analysis found that a single dose of weekly or monthly injectable buprenorphine suppressed opioid withdrawal symptoms throughout the dosing interval, including among participants with relatively low buprenorphine plasma concentrations. Real-world pharmacy data involving more than 30,000 patients also demonstrated utilization across multiple dosage strengths, highlighting the treatment’s dosing flexibility and growing role in individualized opioid use disorder management.
• In March 2026, Collegium Pharmaceutical, a biopharmaceutical company presented new real-world evidence from its portfolio of differentiated pain medications at the PainConnect 2026 conference. The presentations were intended to provide healthcare professionals with practical clinical insights related to the use of advanced pain-management products, including buprenorphine-based therapies such as BELBUCA buccal film. The development reflects Collegium’s continued investment in evidence generation for differentiated drug-delivery formats. Buccal-film technology offers controlled administration through the inner lining of the cheek and supports expanding treatment options for patients requiring long-term chronic pain management. (Source: Collegium Pharmaceutical)